APA

Varpuluoma O., Tasanen K. & Huilaja L. (20191014). Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid". : Journal of the American Academy of Dermatology.

Chicago

Varpuluoma Outi, Tasanen Kaisa and Huilaja Laura. 20191014. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid". : Journal of the American Academy of Dermatology.

Harvard

Varpuluoma O., Tasanen K. and Huilaja L. (20191014). Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid". : Journal of the American Academy of Dermatology.

MLA

Varpuluoma Outi, Tasanen Kaisa and Huilaja Laura. Reply to: "Comment on 'Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study' and a case report of glucagon-like peptide-1 receptor agonist-induced bullous pemphigoid". : Journal of the American Academy of Dermatology. 20191014.